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Abstract: Inflammatory myofibroblastic tumor (IMT) is a rarely described tumor of unknown etiology and pathogenesis. 
It occurs primarily in the lungs, but has occurred in other extra-pulmonary sites. Histologically these lesions appear as an 
inflammatory infiltrate within a variably myofibrotic background. Current evidence shows that inflammatory myofibro-
blastic tumors are neoplastic processes resulting from chromosomal translocations that often cause an overexpression of 
ALK kinase, which is often assessed using immunohistochemical studies. Currently, the biological behavior of oral in-
flammatory myofibroblastic tumor is still uncertain. This article describes the clinical, histological, and operative features 
of a case of IMT of the oral cavity.  
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INTRODUCTION 
Inflammatory Myofibroblastic tumor (IMT) is a rare 
neoplasm consisting of variable numbers of inflammatory 
cells and myofibroblastic spindle cells. It was first observed 
in the lung and described by Brunn in 1939 and was so 
named by Umiker et al. in 1954 because of its clinical and 
radiological behavior that mimics a malignant process [1]. 
The most common sites of involvement include the lung, 
liver and orbit, but it has been reported to occur in nearly 
every site of the body, including the major salivary glands 
and the oral cavity [1-4]. It was called inflammatory pseudo-
tumor (IPT) until 1998 when the term inflammatory myofi-
broblastic tumor (IMT) was proposed as being a more de-
scriptive name [1]. The etiology and pathogenesis of IMT 
remains unclear. Because it can clinically and radiographi-
cally mimic a malignant process, the correct recognition of 
the lesion is important to avoid unnecessary radical surgery. 
Herein, we describe the clinicopathologic features of a case 
of IMT arising in the gingiva.  
CASE REPORT 
A 40-year old female presented with a several month his-
tory of slow growing, painless nodule in anterior maxillary 
gingiva. The lesion was a well circumscribed, raised sessile 
nodule, the same color as the surrounding mucosa, in the 
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Fig. (1). Intraoral photograph at the initial examination. A 15-mm 
painless nodule was observed on anterior maxillary ginigiva.  
 
area between teeth numbers 8 and 9 (Fig. 1). There was no 
bleeding or exudates in the area. The patient’s medical and 
social history was non-contributory and she did not take any 
medications. Radiographic examination was unremarkable. 
The initial clinical differential diagnosis was pyogenic 
granuloma, fibroma, peripheral giant cell lesion and periph-
eral ossifying fibroma.  
The lesion was excised and submitted to the Oral Pathol-
ogy Department at the University of Maryland, Baltimore. 
Gross examination of the specimen revealed a tan soft tissue 
mass, measuring 1.5 x 1.1 x 0.7 cm. Microscopic examina-
tion of the soft tissue specimen, using hematoxylin and eosin 
stain, revealed a mixture predominately composed of in-
flammatory cells, with scant irregularly arranged fascicular 
spindle cells mixed with a prevalent plasma cell infiltrate 
(Fig.  2A,  B). The inflammatory infiltrate also contained 
varying numbers of neutrophils, lymphocytes and macro-
phages. The background stroma showed focal myxoid and Oral Inflammatory Myofibroblastic Tumor  The Open Dentistry Journal, 2011, Volume 5    67 
sclerotic foci. Nuclear atypia was not seen. Immunohisto-
chemical analysis was positive for the expression of muscle 
specific actin (Fig. 2C), anaplastic lymphoma kinase-1 
(ALK-1) (Fig. 2D), and CD-68 (Fig. 2E). 
A final diagnosis of IMT was made. There was no evi-
dence of recurrence after four months of follow-up (Fig. 3). 
DISCUSSION 
IMT is a tumor lesion consisting of variable numbers of 
inflammatory cells and myofibroblastic spindle cells [1]. 
This lesion is rare outside the lung, liver and orbit, with only 
22 cases reported in the literature. Liston et al. in 1981 was 
the first to report IMTs of oral cavity in three children [2]. 
IMT has been described by various names including inflam-
matory pseudotumor (IPT), plasma cell granuloma, benign 
myofibroblastoma, inflammatory fibrosarcoma, histocytoma, 
xanthomatous granuloma, and spindle cell pseudotumor, 
describing its heterogeneous nature [2, 3]. Additionally, sev-
eral histopathologic variants were described by Somersen in 
1978 including; xanthogranuloma, plasma cell (plasma cell 
granuloma), and the sclerosing granulomatous types [5].  
The pathogenesis of IMT remains unknown and contro-
versial and recent evidence shows that IMTs may have a 
different etiology and clinicopathologic features from IPTs 
in the central nervous system, spleen and lymph nodes [6, 7]. 
In intraoral lesions, Brooks et al. distinguished the term 
IMT, which is a neoplastic process from IPT, which is reac-
tive and reparative process [8]. However, hypotheses suggest 
that the lesion maybe infectious, autoimmune, syndromic or 
traumatic in origin. Reports suggest that this tumor in the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A,B) Low and high power views of the lesion, showing a proliferation spindle cells admixed with numerous chronic inflammatory 
cells (neutrophils, lymphocytes, macrophages and plasma cells) in a  fibrous and myxoid background (hematoxylin and eosin, original mag-
nification X4 and X20). C) Low power view of the immunohistochemical expression for smooth muscle actin showing positive spindle cells 
(original magnification X10). D) Immunohistochemical expression of ALK was positive (original magnification X10). E) Immunohisto-
chemical expression of CD-68 showing positivity of histocytes (original magnification X10). 
 
 
 
 
 
 
Fig. (3). Postoperative follow up after four months showing com-
plete healing of the gingiva and no signs of recurrence. Note clo-
sure of diastema with veneer. 68    The Open Dentistry Journal, 2011, Volume 5  Binmadi et al. 
liver maybe associated with inflammatory bowel disease, 
Papillon-Lefevre syndrome, severe congenital neutropenia 
(Kostmann’s disease), or leukemia [1, 8-11]. HIV infection 
has also been associated with this neoplasm in various or-
gans [8, 12]. Interestingly, evidence for a role of Epstein-
Barr viruses has been noted in some cases of IMT in liver, 
spleen and lymph nodes,
 but the role of human herpesvirus-8 
(HHV8) is not clearly associated [6, 8, 13]. Other organisms 
found in association with tumor include actinomycetes found 
in hepatic pseudotumors; or nocardiae and mycoplasma in 
pulmonary pseudotumors [1].  
The terms “inflammatory pseudotumor” and “inflamma-
tory myofibroblastic tumor” were used synonymously in 
most publications, thus we reviewed all 22 cases diagnosed 
in the English literature as IPT or IMT including our case 
(Based on criteria followed by Brooks et al. 2004) Table 1 
[2, 4, 5, 8, 14-27]. The most common intraoral site observed 
was the buccal mucosa, with lesions occurring over a wide 
age range 2 to 82 years with a mean of 32 years and showing 
a 1.6:1 female predilection. The lesion typically presents as a 
firm, indurated swelling and does not produce significant 
systemic symptoms, unlike its counterpart in visceral organs 
[2, 3]. Intrabony presentation of IMT is rare. Only three 
cases have been reported [22, 24, 26]. Brooks et al. de-
scribed a resorptive effect of soft tissue IMT on the under-
ling alveolar bone of edentulous mandible [8]. A CT scan or 
magnetic resonance imaging was done in previous reports 
which characterized lesions with ill-defined infiltrative or 
erosive bony margins [1, 2, 24].  
Histologically, IMT of the oral cavity presents with a 
variable admixture of fascicles of myofibroblastic spindle 
cells mixed with acute and chronic inflammatory cells [2]. 
Atypical mitoses are rare. The stroma is often myxoid or 
collagenous with prominent vasculature. The histologic dif-
ferential diagnosis of IMT is extensive, and includes benign 
and malignant spindle cell tumors such as nodular fasciitis, 
solitary fibrous tumor, benign fibrous histocytoma, calcify-
Table 1. Clinical Features of IPT and IMT Cases in Oral Cavity 
Author 
Age 
(Years) 
Gender  Location  Size in cm  Duration  Follow-up 
Liston et al., 1981 [5]  4 
2 
6 
F 
F 
M 
Buccal mucosa 
Buccal mucosa 
Buccal mucosa 
4x5 
3x5 
4x5 
2 wks 
4days 
1day 
6m; NED 
10m; NED 
NA 
Earl et al., 1993 [14]  44  M  Buccal mucosa  -  -  2yrs; NED 
Ramachandra et al., 1995 
[15] 
77  F  Buccal mucosa  1.5  5m  28yrs; NED 
Shek et al., 1995 [2] 
 
20 
36 
M 
F 
Right cheek 
Left maxilla 
2.0 d 
NA 
1month 
1 year 
13m; NED 
13m; NED 
Ide et al., 1998 [4]  68  F  Buccal mucosa  0.5x0.6  Few years  NA 
Ide et al., 2000 [16]  43  F  Retromolar area  1.0x2.3  1m  1yr; NED 
Cable et al., 2000 [17]   29  F  Hard Palate  1.8x1.8  8wks  NA 
Ide et al., 2000 [18]  27  M  Tongue  1.7  4m  NA 
Pankaj et al., 2001 [19]  -  -  Tongue  -  -  NA 
Jordan et al., 2003 [20]  23  M  Mandible  1.0  1m  NA 
Fang et al., 2004 [21]  23  M  Retromolar area and 
masseter muscle 
2.5x4x5 1m  6m;  NED 
Brooks et al., 2004 [8]  82  F  Mandible  5.0x5.0  2 months  18m; NED 
Poh et al., 2004 [22]  42  F  Mandible  3.0(diameter)  -  6m; NED 
Johann et al., 2008 [23]  33  M  Mandible  3 x2 x2  -  28m; NED 
Oh et al., 2008 [24]  20  F  Mandible  -  3-4months  22m; NED 
Xavier et al., 2009 [25]  23  F  Floor of mouth  3.0(diameter)  3 wks  2yrs; NED 
Eley et al., 2010 [26]  29  M    5.0 (diameter)  1 month  6 yrs, NED 
Satomi et al., 2010 [27]  14  F  Gingiva  3 x 2  3 months  10 yrs; NED 
Present Case  40  F  Gingiva  1.5x1.2  -  4m; NED 
NA, not available; NED, no evidence of disease. Oral Inflammatory Myofibroblastic Tumor  The Open Dentistry Journal, 2011, Volume 5    69 
ing fibrous tumor, myofibroma, fibrosarcoma, follicular 
dendritic cell tumor, and leiomyosarcoma. Histologically, 
IMTs contain a much more prominent inflammatory infil-
trate than nodular fasciitis [13]. Additionally, they lack the 
“c” shaped fascicles, and mucin-rich stroma which is respon-
sible for the characteristic “tissue culture-like or feathery” 
appearance in nodular fasciitis [28]. Solitary fibrous tumor 
was excluded due to the lack of hemangiopericytoma-like 
areas and strong CD34 immunoreactivity [29]. The diagnosis 
of benign fibrous histocytoma was not favored because of 
the lack of characteristic storiform pattern [30]. Calcifying 
fibrous tumor, a rare benign neoplasm, is uniformly hypocel-
lular and contains scattered dystrophic calcifications [13]. 
The diagnosis of myofibroma was excluded due to the lack 
of biphasic growth pattern with hemangiopericytoma-like 
blood vessels [31].  
Fibrosarcoma was excluded due to the lack of malignant 
features, collagenous areas and herringbone pattern that 
characterize it. Additionally, it typically lacks a significant 
inflammatory infiltrate [31, 32]. Follicular dendritic cell tu-
mor is differentiated from IMT by its characteristic distribu-
tion of inflammatory infiltrate admixed with dendritic spin-
dle cells. It is easily distinguished by immunohistochemical 
staining for CD21, CD23 and/or CD35 [2, 8, 33]. If there 
was a predominant lymphocytic and/or plasmacytic compo-
nent, a plasma cell neoplasm (plasmacytoma and multiple 
myeloma) or lymphoma should be excluded. Mucosa-
associated lymphoid tissue–type lymphoma (MALT) may 
show prominent plasma cell differentiation and should be 
added to the list of histologic different diagnoses for IMT of 
salivary glands. No epimyoepithelial islands should be de-
tected, even by immunostaining for cytokeratin, in IMT [1, 
34].
 
In our case, the immunohistochemical analysis revealed 
that the spindle cells were positive for muscle specific actin, 
ALK, and histocytes were positive for CD-68. According to 
the histological and immunohistochemical features of the 
lesion, a final diagnosis IMT was made.  
IMT has shown clonal gene rearrangements of the short 
arm of chromosome 2, some of which result in an ALK gene 
rearrangements; such rearrangements are uncommon in 
adults over 40 years of age with IMT [3, 8, 13].
  Lawrence et 
al. subsequently identified two distinct balanced chromoso-
mal translocations involving the ALK kinase gene. One at 
chromosome 2p23 and other involving either the tropomy-
osin 3 gene (TPM3) at chromosomal locus lq21 or the tro-
pomyosin 4 gene (TPM4) at chromosomal locus 19p13.1, 
resulting in t(1;2) (q21;p23) and t(2;19) (p23;p13.1) translo-
cations, respectively [35]. Other fusion partners of ALK that 
have been documented in IMT include: cysteinyl-tRNA syn-
thetase (CARS), clathrin heavy chain (CLTC), ran-binding 
protein 2 (RAN-BP2), 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP cyclohydrolase 
(ATIC), and SEC31 homolog A (S. cerevisiae) (SEC31L1) 
[36]. CARS gene has been shown to fuse to ALK with a 
t(2;11;2)(p23;p15;q31) [37]. Fusion of ALK with CTLC 
gene localized to 17q23 was detected in two cases of IMT, 
while ALK-ATIC chimeric fusion was detected in an IMT of 
urinary bladder [38, 39]. An intra-abdominal IMT with a 
novel ALK fusion that involved the RANBP2 gene at 2q13 
and SEC31L1, lead to a novel SEC31L1/ALK fusion gene, 
with a translocation t(2;4)(p23;q21) have been reported [40, 
41 ].
  Frequently, these cytogenetic abnormalities (approxi-
mately 50% of IMTs) result in the overexpression of the 
ALK protein kinase often determined by immunohistochem-
istry, and aiding in the diagnosis of IMT. Most other myofi-
broblastic and fibroblastic tumors are negative for ALK [6, 
13]. Other features, such as the presence of ganglion-like 
cells, atypia, p53 expression and aneuploidy may identify 
patients with IMT and those at high malignant risk [3]. 
IMTs are tumors with unpredictable clinical behavior, 
requiring complete surgical excision and continuous moni-
toring of clinical consequences [1].
  Medical management, 
including corticosteroids are not effective in head and neck 
lesions, while considered in the management of orbital IMT 
[1, 3]. There is no evidence of recurrence, malignant trans-
formation, metastasis or death reported with oral IMTs [2]. 
According to the World Health Organization IMTs are clas-
sified as tumors of intermediate biological potential due to a 
tendency of local recurrence and small risk of distance me-
tastasis [13]. IMT in the oral cavity may be confused with 
other malignant tumors on clinical, radiographic, and his-
tologic appearance. Therefore, it is important to recognize 
the distinction among them in order to provide better guide-
lines for treatment and outcome. 
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